- Differences are small in the required amounts of recombinant follicle-stimulating hormone (rFSH), highly purified FSH (HP-FSH), or highly purified human menopausal gonadotrophin (HP-hMG) to reach live birth after in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), according to a systematic review and meta-analysis.
Why this matters
- This study suggests that treatment choice should be based on convenience, availability, cost, and patient preference.
- There was no evidence of a difference in the amount of rFSH vs HP-hMG (mean difference, −37 IU; 95% CI, −115 to 41 IU) or rFSH vs HP-FSH (mean difference, −31 IU; 95% CI, −290 to 228 IU) required to achieve live birth.
- rFSH vs HP-hMG was associated with lower rates of clinical pregnancy (rate ratio [RR], 0.90; 95% CI, 0.81-1.00) and live birth (RR, 0.88; 95% CI, 0.78-0.99) compared with HP-hMG.
- rFSH and HP-FSH were associated with similar rates of clinical pregnancy (RR, 1.03; 95% CI, 0.94-1.13) and live birth (RR, 1.03; 95% CI, 0.90-1.18).
- 28 studies including 7553 women undergoing ovarian stimulation with rFSH, HP-hMG, or HP-FSH were subjected to meta-analysis.
- Funding: None disclosed.
- Heterogeneity between included studies.